U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Ovarian Carcinosarcoma

MedGen UID:
1669017
•Concept ID:
C4727187
•
Neoplastic Process

Definition

The reemergence of ovarian carcinosarcoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Ovarian Carcinosarcoma

Professional guidelines

PubMed

Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Ebata T, Yonemori K, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Fujiwara Y, Kato T, Hasegawa K, Fujiwara K, Tamura K
Oncology 2020;98(10):699-705. Epub 2020 Jun 11 doi: 10.1159/000507333. PMID: 32526764
"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Rauh-Hain JA, Birrer M, Del Carmen MG
Gynecol Oncol 2016 Aug;142(2):248-54. Epub 2016 Jun 16 doi: 10.1016/j.ygyno.2016.06.003. PMID: 27321238
The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC
Gynecol Oncol 2009 Dec;115(3):377-81. Epub 2009 Oct 1 doi: 10.1016/j.ygyno.2009.08.021. PMID: 19800107

Recent clinical studies

Etiology

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
Hollis RL, Croy I, Churchman M, Bartos C, Rye T, Gourley C, Herrington CS
Br J Cancer 2022 Oct;127(6):1034-1042. Epub 2022 Jun 17 doi: 10.1038/s41416-022-01874-8. PMID: 35715633Free PMC Article
Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.
Deli T, Orosz M, Jakab A
Pathol Oncol Res 2020 Jan;26(1):63-78. Epub 2019 Jan 8 doi: 10.1007/s12253-018-00569-x. PMID: 30617760Free PMC Article
"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Rauh-Hain JA, Birrer M, Del Carmen MG
Gynecol Oncol 2016 Aug;142(2):248-54. Epub 2016 Jun 16 doi: 10.1016/j.ygyno.2016.06.003. PMID: 27321238
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I
Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. PMID: 25341582
Chemotherapy for gynecologic cancers.
Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H
Mt Sinai J Med 2009 Dec;76(6):577-88. doi: 10.1002/msj.20143. PMID: 20014427

Diagnosis

Top advances of the year: Ovarian cancer.
Lumish MA, Kohn EC, Tew WP
Cancer 2024 Mar 15;130(6):837-845. Epub 2023 Dec 15 doi: 10.1002/cncr.35135. PMID: 38100616
Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A
Am J Surg Pathol 2023 Jun 1;47(6):635-648. Epub 2023 Apr 6 doi: 10.1097/PAS.0000000000002039. PMID: 37026792
Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases.
Xu Q, Zhang X, Zou Y
J Ovarian Res 2020 Oct 28;13(1):129. doi: 10.1186/s13048-020-00728-2. PMID: 33115531Free PMC Article
"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Rauh-Hain JA, Birrer M, Del Carmen MG
Gynecol Oncol 2016 Aug;142(2):248-54. Epub 2016 Jun 16 doi: 10.1016/j.ygyno.2016.06.003. PMID: 27321238
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I
Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. PMID: 25341582

Therapy

Top advances of the year: Ovarian cancer.
Lumish MA, Kohn EC, Tew WP
Cancer 2024 Mar 15;130(6):837-845. Epub 2023 Dec 15 doi: 10.1002/cncr.35135. PMID: 38100616
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D
J Clin Oncol 2023 Oct 20;41(30):4779-4789. Epub 2023 Jun 26 doi: 10.1200/JCO.22.02624. PMID: 37364223Free PMC Article
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS
J Clin Oncol 2022 Mar 20;40(9):968-977. Epub 2022 Jan 10 doi: 10.1200/JCO.21.02050. PMID: 35007153Free PMC Article
Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.
Deli T, Orosz M, Jakab A
Pathol Oncol Res 2020 Jan;26(1):63-78. Epub 2019 Jan 8 doi: 10.1007/s12253-018-00569-x. PMID: 30617760Free PMC Article
Chemotherapy for gynecologic cancers.
Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H
Mt Sinai J Med 2009 Dec;76(6):577-88. doi: 10.1002/msj.20143. PMID: 20014427

Prognosis

Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A
Am J Surg Pathol 2023 Jun 1;47(6):635-648. Epub 2023 Apr 6 doi: 10.1097/PAS.0000000000002039. PMID: 37026792
Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases.
Xu Q, Zhang X, Zou Y
J Ovarian Res 2020 Oct 28;13(1):129. doi: 10.1186/s13048-020-00728-2. PMID: 33115531Free PMC Article
"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Rauh-Hain JA, Birrer M, Del Carmen MG
Gynecol Oncol 2016 Aug;142(2):248-54. Epub 2016 Jun 16 doi: 10.1016/j.ygyno.2016.06.003. PMID: 27321238
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I
Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. PMID: 25341582
Chemotherapy for gynecologic cancers.
Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H
Mt Sinai J Med 2009 Dec;76(6):577-88. doi: 10.1002/msj.20143. PMID: 20014427

Clinical prediction guides

Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A
Am J Surg Pathol 2023 Jun 1;47(6):635-648. Epub 2023 Apr 6 doi: 10.1097/PAS.0000000000002039. PMID: 37026792
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL, Banet N, Buza N
Pathology 2023 Feb;55(1):8-18. Epub 2022 Nov 23 doi: 10.1016/j.pathol.2022.11.004. PMID: 36503635
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I
Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. PMID: 25341582
Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG
J Reprod Med 2013 Jul-Aug;58(7-8):297-304. PMID: 23947079
Chemotherapy for gynecologic cancers.
Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H
Mt Sinai J Med 2009 Dec;76(6):577-88. doi: 10.1002/msj.20143. PMID: 20014427

Recent systematic reviews

Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: a systematic review and meta-analysis.
Kim Y, Kang GH, Kim H
J Gynecol Oncol 2023 Nov;34(6):e73. Epub 2023 Jun 26 doi: 10.3802/jgo.2023.34.e73. PMID: 37417301Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...